Cargando…
TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy
Nodal peripheral T-cell lymphomas (PTCL), the most common PTCLs, are generally treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-based curative-intent chemotherapy. Recent molecular data have assisted in prognosticating these PTCLs, but most reports lack detailed baselin...
Autores principales: | Johnson, William T., Ganesan, Nivetha, Epstein-Peterson, Zachary D., Moskowitz, Alison J., Stuver, Robert N., Maccaro, Catherine R., Galasso, Natasha, Chang, Tiffany, Khan, Niloufer, Aypar, Umut, Lewis, Natasha E., Zelenetz, Andrew D., Palomba, M. Lia, Matasar, Matthew J., Noy, Ariela, Hamilton, Audrey M., Hamlin, Paul, Caron, Philip C., Straus, David J., Intlekofer, Andrew M., Lee Batlevi, Connie, Kumar, Anita, Owens, Colette N., Sauter, Craig S., Falchi, Lorenzo, Lue, Jennifer K., Vardhana, Santosha A., Salles, Gilles, Dogan, Ahmet, Schultz, Nikolaus D., Arcila, Maria E., Horwitz, Steven M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10480533/ https://www.ncbi.nlm.nih.gov/pubmed/37078708 http://dx.doi.org/10.1182/bloodadvances.2023009953 |
Ejemplares similares
-
Retrospective characterization of nodal marginal zone lymphoma
por: Stuver, Robert, et al.
Publicado: (2023) -
Excellent response to very-low-dose radiation (4 Gy) for indolent B-cell lymphomas: is 4 Gy suitable for curable patients?
por: Imber, Brandon S., et al.
Publicado: (2021) -
Predictors of survival in patients with MALT lymphoma: a retrospective, case-control study
por: Qi, Shunan, et al.
Publicado: (2022) -
Comparative efficacy and tolerability of novel agents vs chemotherapy in relapsed and refractory T-cell lymphomas: a meta-analysis
por: Shafagati, Nazila, et al.
Publicado: (2022) -
Prognostic model using (18)F-FDG PET radiomics predicts progression-free survival in relapsed/refractory Hodgkin lymphoma
por: Driessen, Julia, et al.
Publicado: (2023)